San Francisco, CA – June 30, 2025. Aktana, the leader in intelligent customer engagement for life sciences, released this week the Agentic AI Intelligence Briefing, a free resource designed to help life sciences organizations adopt AI in a manner that is transparent, trusted, and operationally feasible.

The briefing, introduced in a new open letter authored by CEO John Vitalie, reflects Aktana’s industry vision for AI capabilities that directly address data silos, system incompatibility and broken processes. Vitalie outlines why responsible AI implementation must be rooted in human oversight, strategic continuity, and integration with existing systems. The briefing distills Aktana’s enterprise deployment experience into 20+ clear, actionable FAQs, specifically tailored to the needs of commercial, medical, field, and brand teams.

“We believe that embracing AI doesn’t mean sidelining the very human expertise, collective experience, and individual judgment that drives results across our industry,” said John Vitalie, CEO of Aktana. “Our vision is clear: AI should empower your teams, augment their capabilities, align objectives to execution, and elevate human decision-making rather than replace it.”

The Agentic AI Intelligence Briefing focuses on three main topics—human oversight and adoption, transparency and explainability, and context-aware orchestration—while addressing critical challenges such as CRM transitions.

As more pharmaceutical organizations consider scaling AI beyond pilot programs, Aktana emphasizes a pragmatic, phased approach to automation, prioritizing interoperability, trust, and strategic alignment.

“The pharmaceutical industry’s omnichannel landscape is inherently complex, characterized by transitioning CRM systems, siloed field and digital operations, intricate product portfolios, and stringent regulatory constraints,” said Derek Choy, Co-founder and Chief Product Officer. “Recognizing these challenges, our approach emphasizes practicality, ensuring that AI adoption integrates seamlessly with existing workflows, systems, and regulatory frameworks.”

The briefing and letter underscore Aktana’s belief that Agentic AI must operate effectively within the constraints and complexity of life sciences. This includes supporting CRM transitions, workflow optimizations and evolving brand strategies without disrupting ongoing operations.

To download the full briefing or read the open letter, visit: Full Briefing